Precision Biosciences (DTIL) Equity Average (2018 - 2026)

Precision Biosciences (DTIL) has 9 years of Equity Average data on file, last reported at $84.2 million in Q1 2026.

• Equity Average for Q1 2026 came in at $84.2 million, up 59.23% year-over-year; the trailing twelve-month figure through Mar 2026 was $84.2 million (up 59.23% YoY), and the FY2025 annual result was $74.3 million, up 97.52% from the prior year.
• Equity Average climbed to $84.2 million in Q1 2026 per DTIL's latest filing, from $54.4 million in the prior quarter.
• Over five years, Equity Average peaked at $93.7 million in Q3 2022 and troughed at $24.0 million in Q4 2023.
• A 5-year average of $55.8 million and a median of $54.4 million in 2025 frame the typical range for Equity Average.
• The sharpest annual moves came in 2023 and 2024: Equity Average plunged 66.91% in 2023, then soared 153.02% in 2024.
• A 5-year view of Equity Average shows it stood at $72.4 million in 2022, then slumped by 66.91% to $24.0 million in 2023, then soared by 153.02% to $60.6 million in 2024, then fell by 10.21% to $54.4 million in 2025, then jumped by 54.62% to $84.2 million in 2026.
• Business Quant data shows DTIL's Equity Average at $84.2 million in Q1 2026, $54.4 million in Q4 2025, and $25.3 million in Q3 2025.